Spelling suggestions: "subject:"hypouricemia"" "subject:"hypouricaemia""
1 |
The prevalence and characteristics of hypouricemia: a descriptive study of medical check-up and administrative claims data / 低尿酸血症の有病割合とその特徴:レセプトおよび健康診断データを用いた記述疫学研究Koto, Ruriko 23 March 2023 (has links)
京都大学 / 新制・課程博士 / 博士(社会健康医学) / 甲第24537号 / 社医博第129号 / 新制||社医||12(附属図書館) / 京都大学大学院医学研究科社会健康医学系専攻 / (主査)教授 中山 健夫, 教授 近藤 尚己, 教授 山本 洋介 / 学位規則第4条第1項該当 / Doctor of Public Health / Kyoto University / DFAM
|
2 |
SLC22A12 W258X FREQUENCY ACCORDING TO SERUM URIC ACID LEVEL AMONG JAPANESE HEALTH CHECKUP EXAMINEESHAMAJIMA, NOBUYUKI, NAITO, MARIKO, MORITA, EMI, ITO, YOSHINORI, SUZUKI, KOJI, OKADA, RIEKO, KURIKI, SAYAKA 02 1900 (has links)
No description available.
|
3 |
Vliv polymorfismu urátových transportérů na exkreci kyseliny močové / The effect of urate transporter polymorphisms on uric acid excretionMančíková, Andrea January 2020 (has links)
Uric acid excretion disorders are the most common cause of primary dysuricemia. The kidneys eliminate two-thirds of uric acid production and the other third is eliminated in the gastrointestinal tract. Renal reabsorption and secretion occur through the polarised epithelial cells in the proximal tubules. Uric acid transporters are expressed on these cell membranes. Reabsorption deficiency leads to hypouricemia and elevated fraction excretion associated with urolithiasis, nephrolithiasis or acute renal injury. Decreased uric acid secretion in the kidneys and small intestine leads to hyperuricemia, which develops into gout in 10% of individuals. Genome wide association studies detected a strong effect of SLC22A12 (URAT1), SLC2A9 (GLUT9) reabsorbing transporters and ABCG2 (ABCG2) secreting transporter on uric acid serum concentration variability. This thesis aimed to map out urate transporter allelic variants in a cohort of primary dysuricemia patients and identification of the variants causing defective uric acid excretion. Six non-synonymous variants were described in SLC22A12 (URAT1) and SLC2A9 (GLUT9) genes in hypouricemic individuals, which had not been identified previously in any population studies. Significant decreases in uric acid transport have been demonstrated experimentally in vitro,...
|
4 |
Vliv polymorfismu urátových transportérů na exkreci kyseliny močové / The effect of urate transporter polymorphisms on uric acid excretionMančíková, Andrea January 2020 (has links)
Uric acid excretion disorders are the most common cause of primary dysuricemia. The kidneys eliminate two-thirds of uric acid production and the other third is eliminated in the gastrointestinal tract. Renal reabsorption and secretion occur through the polarised epithelial cells in the proximal tubules. Uric acid transporters are expressed on these cell membranes. Reabsorption deficiency leads to hypouricemia and elevated fraction excretion associated with urolithiasis, nephrolithiasis or acute renal injury. Decreased uric acid secretion in the kidneys and small intestine leads to hyperuricemia, which develops into gout in 10% of individuals. Genome wide association studies detected a strong effect of SLC22A12 (URAT1), SLC2A9 (GLUT9) reabsorbing transporters and ABCG2 (ABCG2) secreting transporter on uric acid serum concentration variability. This thesis aimed to map out urate transporter allelic variants in a cohort of primary dysuricemia patients and identification of the variants causing defective uric acid excretion. Six non-synonymous variants were described in SLC22A12 (URAT1) and SLC2A9 (GLUT9) genes in hypouricemic individuals, which had not been identified previously in any population studies. Significant decreases in uric acid transport have been demonstrated experimentally in vitro,...
|
Page generated in 0.0243 seconds